BridgeBio Pharma (BBIO) Other Gross PP&E Adjustments (2019 - 2025)
BridgeBio Pharma (BBIO) has disclosed Other Gross PP&E Adjustments for 7 consecutive years, with -$28.8 million as the latest value for Q4 2025.
- Quarterly Other Gross PP&E Adjustments fell 7.05% to -$28.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28.8 million through Dec 2025, down 7.05% year-over-year, with the annual reading at -$28.8 million for FY2025, 7.05% down from the prior year.
- Other Gross PP&E Adjustments hit -$28.8 million in Q4 2025 for BridgeBio Pharma, down from -$7.3 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$7.3 million in Q3 2025 to a low of -$29.4 million in Q4 2023.
- Historically, Other Gross PP&E Adjustments has averaged -$16.3 million across 5 years, with a median of -$14.3 million in 2022.
- Biggest five-year swings in Other Gross PP&E Adjustments: crashed 45.96% in 2021 and later soared 37.11% in 2022.
- Year by year, Other Gross PP&E Adjustments stood at -$26.1 million in 2021, then fell by 2.57% to -$26.8 million in 2022, then dropped by 9.53% to -$29.4 million in 2023, then increased by 8.48% to -$26.9 million in 2024, then fell by 7.05% to -$28.8 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for BBIO at -$28.8 million in Q4 2025, -$7.3 million in Q3 2025, and -$7.6 million in Q2 2025.